Sleeping sickness target deciphered
Researchers at the University of Luebeck have revealed the structure of the IMP dehydrogenase, a central target of T. brucei, which causes sleeping sickness.
UK researchers present dengue virus transmission map
Scientists at Imperial College London have created a worldwide atlas of dengue virus transmission with much higher spatial resolution than any previous regional- or global-scale estimates.
AMR: IMIs Enable project reaches endpoints
The ENABLE project has achieved its initial goals to identify three antibacterial leads, select two antibacterial development candidates and advance one compound into Phase I development.
MercachemSyncom, Bionetix, and ProQinase ink AML contract
Bionetix, ProQinase, and MercachemSyncom have announced that they will jointly develop a new AML drug, from target identification to clinical testing
iOnctura SA bags 15m in Series A round
Merck KGaAs 2017 Swiss cancer spin-out iOnctura SA has raised 15m to bring its PI3K? inhibitor and autotaxin inhibitor to the clinic.
BioNTech acquires Neon at cheapest for $67m
mRNA cancer neoantigen specialist BioNTech AG is set to buy all shares of Neon Therapeutics, Inc. expanding its pipeline of neoantigen-targeting therapies and getting foothold in the US.
New stromal target overcomes cancer resistance
British researchers have identified several small molecule drugs that sensitized B cell cancers to chemotherapy and extended survival in mouse models.
Astellas and Adaptimmune team up in CAR-T development
Adaptimmune Therapeutics plc and Japanese Astellas Pharma, Inc. have signed a discovery partnership to develop off-the-shelf allogeneic T cell-based cancer therapies from stem cells.
Illumina embraces Roche
Twelve years after Roches $6.8bn hostile takeover bid for Illumina, the companies have entered into a 15-year partnership to boost personalised NGS-based cancer testing.